Jasper Therapeutics (NASDAQ:JSPR) Rating Reiterated by HC Wainwright

Jasper Therapeutics (NASDAQ:JSPR)‘s stock had its “buy” rating restated by HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $65.00 price objective on the stock. HC Wainwright’s price target points to a potential upside of 257.54% from the company’s previous close.

Several other brokerages also recently issued reports on JSPR. JMP Securities reiterated a “market outperform” rating and set a $70.00 price target on shares of Jasper Therapeutics in a report on Friday, September 27th. Stifel Nicolaus began coverage on Jasper Therapeutics in a report on Thursday, June 27th. They issued a “buy” rating and a $86.00 target price for the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Jasper Therapeutics in a research note on Monday, September 9th. Evercore ISI restated an “outperform” rating and set a $65.00 price target on shares of Jasper Therapeutics in a report on Monday, August 26th. Finally, Royal Bank of Canada dropped their price objective on shares of Jasper Therapeutics from $70.00 to $68.00 and set an “outperform” rating for the company in a report on Wednesday, August 14th. Ten equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $74.86.

Jasper Therapeutics Stock Down 0.5 %

NASDAQ:JSPR opened at $18.18 on Tuesday. The firm has a market capitalization of $273.86 million, a PE ratio of -3.23 and a beta of 2.21. Jasper Therapeutics has a twelve month low of $4.00 and a twelve month high of $31.01. The stock’s 50-day simple moving average is $19.00 and its 200 day simple moving average is $21.51.

Jasper Therapeutics (NASDAQ:JSPR) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.97) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.09) by $0.12. On average, analysts anticipate that Jasper Therapeutics will post -4.16 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of JSPR. StemPoint Capital LP bought a new position in shares of Jasper Therapeutics during the 1st quarter worth approximately $3,794,000. Ikarian Capital LLC acquired a new position in shares of Jasper Therapeutics during the first quarter valued at about $3,088,000. Russell Investments Group Ltd. bought a new stake in shares of Jasper Therapeutics during the first quarter worth about $2,343,000. Bank of New York Mellon Corp bought a new stake in Jasper Therapeutics during the 2nd quarter worth approximately $740,000. Finally, Concurrent Investment Advisors LLC bought a new position in shares of Jasper Therapeutics in the first quarter valued at approximately $599,000. Institutional investors and hedge funds own 79.85% of the company’s stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.